Elevation Oncology, Inc. (ELEV)
Elevation Oncology, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Boston, NY, US. The stock last traded at $0.36, down 2.12% on the session, giving a market capitalisation of $21.6M. On trailing twelve-month figures it carries a trailing P/E of -0.47, a net margin of 0.0%. Its beta of 1.50 implies it has historically moved more than the broad market.
Elevation Oncology, Inc. is a clinical-stage biopharmaceutical company operating in the United States, committed to developing targeted cancer therapies for patients with specific genetic profiles. Its leading drug candidate is seribantumab, an anti-HER3 monoclonal antibody currently being evaluated in the Phase II CRESTONE trial. This study focuses on treating advanced solid tumors that harbor a neuregulin-1 fusion. The company was established in 2019 and is headquartered in New York, New York.
Elevation Oncology, Inc. is most often compared with the following Healthcare names: